1. Scrip
  2. >>Business
  3. >>Strategy

GlaxoSmithKline Breaks Out of Its Small-Molecule Mind-Set

 
• By Mark Ratner

Following similar moves by many of its Big Pharma peers, GSK is buying into large molecules, big time. In December 2006, it paid $454 million in cash for next-generation antibody specialist Domantis. Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for an antibody program from Genmab AS. For investors in privately held Domantis, whose most advanced drug candidate is preclinical, the acquisition was a much earlier than-anticipated exit.

Following similar moves by many of its Big Pharma peers, GlaxoSmithKline PLC is buying into large molecules, big time. In December 2006, it paid £230mm ($454 million) in cash for next-generation antibody specialist Domantis Ltd.[See Deal] Later that month, the pharmaceutical firm committed over $2 billion in up-fronts, milestones, and equity for Genmab AS ' HuMax-CD20 (ofatumumab) fully human monoclonal antibody, plus other anti-CD20 antibodies that GenMab may develop. [See Deal](See "Genmab/GSK: An Impressive Display of Biotech’s Increased Leverage," IN VIVO, January 2007 Also see "Genmab/GSK: An Impressive Display of Biotech's Increased Leverage" - In Vivo, 1 January, 2007..)

The Domantis acquisition was GSK’s first external transaction in the area and a direct consequence of an internal review by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.